DG Dispatch - AAN: Epileptic Drug Used To Treat MS Symptom
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG Dispatch - AAN: Epileptic Drug Used To Treat MS Symptom

By Cameron Johnston
Special to DG News

TORONTO, ON -- April 20, 1999 -- Low-dose Neurontin (gabapentin) may be useful in treating painful night-time spasms in adults with multiple sclerosis (MS), according to a study presented at the American Academy of Neurology meeting being held in Toronto from April 17-24.

Parke-Davis’ Neurontin is currently used to treat partial generalised epileptic seizures in children.

People with epilepsy may take up to 1,800 mg/day of the drug, while patients enrolled in the MS study were given no more than 600 mg/day. They were then tested after two weeks and eight weeks of treatment. Neurologist Gianluigi Marcardi, from Genoa, Italy, reported that 20 out of 24 patients who used gabapentin reported that their spasms either cleared up completely or were significantly reduced over the course of the study.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities